BOLT

Bolt Biotherapeutics, Inc.

3.23 USD

Last updated Sep 5, 12:15 UTC

Yesterday HIGH

$4

Yesterday LOW

$3.84

52w HIGH

$7.09

52w LOW

$3.13

EPS

-4.57

PE

-0.71

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

Bolt Biotherapeutics, Inc. stock is down -16.54% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 5 September’s closed higher than August.

Benzinga Insights

Wed Aug 12, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION) shares rose
Benzinga Newsdesk

Wed Aug 12, 2026

Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Benzinga Newsdesk

Tue Aug 11, 2026

Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share
Benzinga Newsdesk

Fri May 29, 2026

Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.
Benzinga Newsdesk

Thu May 28, 2026

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
Benzinga Newsdesk

Tue May 12, 2026

Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share